2026-04-29T02:37:58Zhttps://repisalud.isciii.es/rest/oai/request
oai:repisalud.isciii.es:20.500.12105/231682024-11-28T22:04:20Zcom_20.500.12105_15322com_20.500.12105_2051col_20.500.12105_16967
Repisalud author García-Cosío, Borja author Shafiek, Hanaa author Toledo Pons, Nuria author Iglesias, Amanda author Barcelo, Margalida author Represas-Represas, Cristina author Comeche, Lorena author Catalan, Pablo author Fernandez-Villar, Alberto author Lopez-Campos, Jose Luis author Echave-Sustaeta, Jose M author Soler-Cataluna, Juan Jose 2024-09-18T06:42:08Z 2024-09-18T06:42:08Z 2021 Cosio BG, Shafiek H, Toledo-Pons N, Iglesias A, Barcelo M, Represas-Represas C, et al. Characterization of COPD Admissions During the First COVID-19 Outbreak. Int J Chronic Obstr Pulm Dis. 2021;16:1549-54. 1178-2005 https://hdl.handle.net/20.500.13003/19487 https://hdl.handle.net/20.500.12105/23168 34113088 10.2147/COPD.S312493 International Journal of Chronic Obstructive Pulmonary Disease 2-s2.0-85108032821 662305300001 L2007504226 Purpose: Exacerbations of COPD (ECOPD) are a frequent cause of hospitalization that seemed to ameliorate during the COVID outbreak. We aimed to evaluate the clinical characteristics of COPD-related hospital admissions and mortality in relation to the presence of COVID-19. Patients and Methods: We conducted a case-control study of patients admitted in four teaching hospitals throughout Spain between March 15 and April 30, 2020. Hospital admissions of respiratory cause with and without PCR-proven SARS-CoV-2 infection in patients with COPD were evaluated. Baseline and episode-related clinical characteristics were analyzed. Logistic regression analysis was performed to evaluate the risk for mortality. Results: During the study period, 2101 patients were admitted for respiratory worsening, 1200 (57.1%) with COVID-19. A total of 228 (10.8%) were admitted due to COPD worsening, of whom 52 (22.8%) tested positive for COVID-19. COPD patients with COVID-19, when compared to those without COVID-19, were more frequently males with better lung function (FEV1 postbronchodilator 71% vs 46% respectively, p<0.001) and had higher mortality (44.9% vs 13.6% respectively, p<0.001) despite similar age, comorbidities, total days of hospitalization and admission to intensive care unit. COVID-19 and eosinopenia were the strongest risk factors for mortality in the multivariate analysis in the overall COPD population. Inhaled corticosteroid use was not associated to mortality. Conclusion: Hospitalizations for ECOPD without COVID-19 were more frequent than COPD with COVID-19 during the first outbreak, but the latter were associated with higher mortality and low eosinophil counts that warrant further analysis. eng COPD exacerbation Mortality Inhaled corticosteroids Hospitalization Characterization of COPD Admissions During the First COVID-19 Outbreak research article